Page 53 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine EZH2 inhibition in ARID1A-deficient TNBC

2013;15(2):149-160. radiation therapies. Lab Invest. 2022;102(2):185-193.
doi: 10.1093/neuonc/nos285 doi: 10.1038/s41374-021-00700-8
104. Agrawal R, Chen M, Bukhari Z, Ogunwobi OO, Haseeb MA, 114. Park Y, Chui MH, Suryo Rahmanto Y, et al. Loss of ARID1A
Martello LA. EZH2 Downregulation augments the effect of in tumor cells renders selective vulnerability to combined
irradiation in reducing pancreatic cancer cell proliferation ionizing radiation and PARP inhibitor therapy. Clin Cancer
in vitro. Ann Clin Lab Sci. 2020;50(1):45-56. Res. 2019;25(18):5584-5594.
105. Cai MY, Tong ZT, Zhu W, et al. H3K27me3 protein is a doi: 10.1158/1078-0432.Ccr-18-4222
promising predictive biomarker of patients’ survival and
chemoradioresistance in human nasopharyngeal carcinoma. 115. Neagu AN, Bruno P, Johnson KR, Ballestas G, Darie CC.
Mol Med. 2011;17(11-12):1137-1145. Biological basis of breast cancer-related disparities in
precision oncology era. Int J Mol Sci. 2024;25(7):4113.
doi: 10.2119/molmed.2011.00054
doi: 10.3390/ijms25074113
106. Kuser-Abali G, Gong L, Yan J, et al. An EZH2-mediated
epigenetic mechanism behind P53-dependent tissue 116. Werner RJ, Kelly AD, Issa JJ. Epigenetics and precision
sensitivity to DNA damage. Proc Natl Acad Sci U S A. oncology. Cancer J. 2017;23(5):262-269.
2018;115(13):3452-3457.
doi: 10.1097/ppo.0000000000000281
doi: 10.1073/pnas.1719532115
117. Durán M, Faull I, Lastra E, Laes JF, Rodrigo AB, Sánchez-
107. Brenneman RJ, Sharifai N, Fischer-Valuck B, et al. Abscopal Escribano R. ARID1A genomic alterations driving
effect following proton beam radiotherapy in a patient with microsatellite instability through somatic MLH1 methylation
inoperable metastatic retroperitoneal sarcoma. Front Oncol. with response to immunotherapy in metastatic lung
2019;9:922. adenocarcinoma: A case report. J Med Case Rep. 2021;15(1):89.
doi: 10.3389/fonc.2019.00922 doi: 10.1186/s13256-020-02589-1
108. Wu C, Jin X, Yang J, et al. Inhibition of EZH2 by chemo- and 118. Goswami S, Chen Y, Anandhan S, et al. ARID1A mutation
radiotherapy agents and small molecule inhibitors induces plus CXCL13 expression act as combinatorial biomarkers to
cell death in castration-resistant prostate cancer. Oncotarget.
2016;7(3):3440-3452. predict responses to immune checkpoint therapy in mUCC.
Sci Transl Med. 2020;12(548):eabc4220.
doi: 10.18632/oncotarget.6497
doi: 10.1126/scitranslmed.abc4220
109. Klaus CR, Keats JA, Smith JJ, et al. Tazemetostat displays
synergistic antiproliferative activity with backbone therapies 119. Li L, Li M, Jiang Z, Wang X. ARID1A mutations are associated
in preclinical models of AT/RT and MRT. Cancer Res. with increased immune activity in gastrointestinal cancer.
2017;77(13):1944. Cells. 2019;8(7):678.
doi: 10.1158/1538-7445.AM2017-1944 doi: 10.3390/cells8070678
110. Gounder MM, Zhu G, Roshal L, et al. Immunologic correlates 120. Pignata S, Califano D, Lorusso D, et al. MITO END-
of the abscopal effect in a SMARCB1/INI1-negative 3: Efficacy of avelumab immunotherapy according to
poorly differentiated chordoma after EZH2 inhibition and molecular profiling in first-line endometrial cancer therapy.
radiotherapy. Clin Cancer Res. 2019;25(7):2064-2071. Ann Oncol. 2024;35(7):667-676.
doi: 10.1158/1078-0432.Ccr-18-3133 doi: 10.1016/j.annonc.2024.04.007
111. Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, et al. Evidence 121. Zhou H, Sun D, Song S, et al. Efficacy of immunotherapy
for early stage anti-tumor immunity elicited by spatially in arid1a-mutant solid tumors: A single-center retrospective
fractionated radiotherapy-immunotherapy combinations. study. Discov Oncol. 2024;15(1):213.
Radiat Res. 2020;194(6):688-697.
doi: 10.1007/s12672-024-01074-1
doi: 10.1667/rade-20-00065.1
122. Nutt SL, Keenan C, Chopin M, Allan RS. EZH2 function in
112. Lukas L, Zhang H, Cheng K, Epstein A. Immune priming immune cell development. Biol Chem. 2020;401(8):933-943
with spatially fractionated radiation therapy. Curr Oncol
Rep. 2023;25(12):1483-1496. doi: 10.1515/hsz-2019-0436
doi: 10.1007/s11912-023-01473-7 123. Kim HJ, Cantor H, Cosmopoulos K. Overcoming immune
checkpoint blockade resistance via EZH2 inhibition. Trends
113. Qi L, Lindsay H, Kogiso M, et al. Evaluation of an EZH2 inhibitor Immunol. 2020;41(10):948-963.
in patient-derived orthotopic xenograft models of pediatric
brain tumors alone and in combination with chemo- and doi: 10.1016/j.it.2020.08.010

Volume 3 Issue 1 (2025) 45 doi: 10.36922/arnm.5132